Query: Pharmacological stabilization of ryanodine receptor 1 (RyR1) leak in sarcopenia: small-molecule therapeutics that normalize diastolic Ca2+ leak in aged human myotubes or isolated muscle fibers, with genetic and functional target validation, efficacy in relevant models, and preliminary human safety data

The concept of pharmacologically stabilizing RyR1 to normalize diastolic Ca2+ leak in aged skeletal muscle is supported by a robust preclinical rationale, although direct clinical evaluation in sarcopenia remains largely unexplored. No registered clinical trials targeting RyR1-mediated Ca2+ leak in sarcopenia exist to date (Clinical Trials Search: ryanodine receptor 1 AND sarcopenia AND (therapeutic OR inhibitor OR leak OR Ca2+)), highlighting an evidentiary gap in human studies.

Preclinical research in Duchenne muscular dystrophy (DMD) and related muscle pathologies has provided extensive genetic and functional validation for modulating RyR1 function. In these disease models, RyR1 becomes hypernitrosylated or otherwise oxidatively modified, rendering the channel leaky and leading to excessive diastolic calcium release. Such dysregulation contributes to intracellular Ca2+ overload and muscle dysfunction (dubinin2023ionchannelsof pages 14-15). Small molecules known as rycals have been designed to stabilize the RyR complex, reducing pathological Ca2+ leak and thereby preserving muscle function, as evidenced by genetic and functional target validation studies in animal models (spinazzola2016pharmacologicaltherapeuticstargeting pages 11-13).

Structural studies using cryo-electron microscopy and related techniques have elucidated key binding sites on RyR1 that allow for pharmacological intervention. Insight into the precise structural determinants of channel gating and leakiness has informed the design of small molecules aimed at targeting specific modulatory domains of RyR1. This structural framework supports the development of compounds that can effectively restore proper channel closure during diastole and minimize aberrant Ca2+ efflux in aged muscle fibers (hadiatullah2022structuralinsightinto pages 15-16).

In preclinical models that recapitulate aspects of muscle aging and dystrophic pathology, stabilization of RyR1 leak via small molecules has been shown to improve excitation–contraction coupling and overall muscle performance. Animal studies offer compelling evidence that pharmacological agents can reverse or mitigate the detrimental effects of chronic diastolic Ca2+ leak, thereby normalizing intracellular Ca2+ dynamics and reducing associated muscle weakness and degeneration (dubinin2023ionchannelsof pages 22-23, spinazzola2016pharmacologicaltherapeuticstargeting pages 13-14).

Parallel studies in aged muscle cells and isolated myotubes, although less extensive than those in dystrophic models, indicate that oxidative modifications of RyR1 are similarly implicated in sarcopenia. These findings suggest that small-molecule therapeutics developed for RyR stabilization in DMD may be translatable to sarcopenia. Mechanistic insights point toward a convergence of pathways involving increased oxidative stress, impaired SERCA function, and resulting Ca2+ dysregulation, which collectively underlie muscle aging (dubinin2023ionchannelsof pages 8-10, bellissimo2023explorationofthe pages 10-14).

Preliminary human safety data emerging from early clinical trials in contexts of RyR1-related myopathies and RyR modulators, such as those involving compounds like S107 and ARM210/S48168, further bolster the translational promise of this strategy. Although these studies have largely focused on dystrophic conditions, they provide important safety and efficacy benchmarks that could inform future investigations in sarcopenia (spinazzola2016pharmacologicaltherapeuticstargeting pages 24-25).

Open Targets data currently reveal a modest association between RYR1 and sarcopenia, underscoring the need for more comprehensive experimental efforts to validate RyR1 as a therapeutic target in the context of muscle aging (OpenTargets Search: sarcopenia-RYR1). In summary, while extensive preclinical evidence supports the use of small-molecule therapeutics to stabilize RyR1-mediated Ca2+ leak—with genetic and functional validation, efficacy in relevant models, and emerging human safety data—the translational step into sarcopenia-specific clinical studies remains to be fully addressed (dubinin2023ionchannelsof pages 21-22, hadiatullah2022structuralinsightinto pages 20-21).

References:
1. (dubinin2023ionchannelsof pages 14-15): Mikhail V. Dubinin and Konstantin N. Belosludtsev. Ion channels of the sarcolemma and intracellular organelles in duchenne muscular dystrophy: a role in the dysregulation of ion homeostasis and a possible target for therapy. International Journal of Molecular Sciences, 24:2229, Jan 2023. URL: https://doi.org/10.3390/ijms24032229, doi:10.3390/ijms24032229. This article has 27 citations and is from a peer-reviewed journal.

2. (dubinin2023ionchannelsof pages 22-23): Mikhail V. Dubinin and Konstantin N. Belosludtsev. Ion channels of the sarcolemma and intracellular organelles in duchenne muscular dystrophy: a role in the dysregulation of ion homeostasis and a possible target for therapy. International Journal of Molecular Sciences, 24:2229, Jan 2023. URL: https://doi.org/10.3390/ijms24032229, doi:10.3390/ijms24032229. This article has 27 citations and is from a peer-reviewed journal.

3. (hadiatullah2022structuralinsightinto pages 15-16): Hadiatullah Hadiatullah, Zhao He, and Zhiguang Yuchi. Structural insight into ryanodine receptor channelopathies. Frontiers in Pharmacology, May 2022. URL: https://doi.org/10.3389/fphar.2022.897494, doi:10.3389/fphar.2022.897494. This article has 16 citations and is from a peer-reviewed journal.

4. (spinazzola2016pharmacologicaltherapeuticstargeting pages 11-13): Janelle M. Spinazzola and Louis M. Kunkel. Pharmacological therapeutics targeting the secondary defects and downstream pathology of duchenne muscular dystrophy. Expert Opinion on Orphan Drugs, 4:1179-1194, Oct 2016. URL: https://doi.org/10.1080/21678707.2016.1240613, doi:10.1080/21678707.2016.1240613. This article has 42 citations.

5. (OpenTargets Search: sarcopenia-RYR1): Open Targets Query (sarcopenia-RYR1, 5 results). Ochoa, D. et al. (2023). The next-generation Open Targets Platform: reimagined, redesigned, rebuilt. Nucleic Acids Research.

6. (bellissimo2023explorationofthe pages 10-14): CA Bellissimo. Exploration of the mitochondria as a potential therapeutic target in duchenne muscular dystrophy. Unknown journal, 2023.

7. (dubinin2023ionchannelsof pages 8-10): Mikhail V. Dubinin and Konstantin N. Belosludtsev. Ion channels of the sarcolemma and intracellular organelles in duchenne muscular dystrophy: a role in the dysregulation of ion homeostasis and a possible target for therapy. International Journal of Molecular Sciences, 24:2229, Jan 2023. URL: https://doi.org/10.3390/ijms24032229, doi:10.3390/ijms24032229. This article has 27 citations and is from a peer-reviewed journal.

8. (spinazzola2016pharmacologicaltherapeuticstargeting pages 13-14): Janelle M. Spinazzola and Louis M. Kunkel. Pharmacological therapeutics targeting the secondary defects and downstream pathology of duchenne muscular dystrophy. Expert Opinion on Orphan Drugs, 4:1179-1194, Oct 2016. URL: https://doi.org/10.1080/21678707.2016.1240613, doi:10.1080/21678707.2016.1240613. This article has 42 citations.

9. (spinazzola2016pharmacologicaltherapeuticstargeting pages 24-25): Janelle M. Spinazzola and Louis M. Kunkel. Pharmacological therapeutics targeting the secondary defects and downstream pathology of duchenne muscular dystrophy. Expert Opinion on Orphan Drugs, 4:1179-1194, Oct 2016. URL: https://doi.org/10.1080/21678707.2016.1240613, doi:10.1080/21678707.2016.1240613. This article has 42 citations.

10. (dubinin2023ionchannelsof pages 21-22): Mikhail V. Dubinin and Konstantin N. Belosludtsev. Ion channels of the sarcolemma and intracellular organelles in duchenne muscular dystrophy: a role in the dysregulation of ion homeostasis and a possible target for therapy. International Journal of Molecular Sciences, 24:2229, Jan 2023. URL: https://doi.org/10.3390/ijms24032229, doi:10.3390/ijms24032229. This article has 27 citations and is from a peer-reviewed journal.

11. (hadiatullah2022structuralinsightinto pages 20-21): Hadiatullah Hadiatullah, Zhao He, and Zhiguang Yuchi. Structural insight into ryanodine receptor channelopathies. Frontiers in Pharmacology, May 2022. URL: https://doi.org/10.3389/fphar.2022.897494, doi:10.3389/fphar.2022.897494. This article has 16 citations and is from a peer-reviewed journal.
